Predicted protein targets (top 15)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.49 |
| ▸ | HPGD | P15428 | 2/20 | 0.36 |
| ▸ | ALOX15 | P16050 | 1/20 | 0.36 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.36 |
| ▸ | TPSAB1 | Q15661 | 1/20 | 0.36 |
| ▸ | LMNA | P02545 | 1/20 | 0.35 |
| ▸ | TSHR | P16473 | 1/20 | 0.35 |
| ▸ | GAA | P10253 | 1/20 | 0.35 |
| ▸ | HTT | P42858 | 3/20 | 0.34 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.34 |
| ▸ | HDAC1 | Q13547 | 3/20 | 0.34 |
| ▸ | HDAC2 | Q92769 | 3/20 | 0.34 |
| ▸ | SUCNR1 | Q9BXA5 | 1/20 | 0.33 |
| ▸ | POLB | P06746 | 1/20 | 0.32 |
| ▸ | ATM | Q13315 | 1/20 | 0.32 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL23869734 | 0.87 | SMN1; SMN2 (0.35) | SMN1; SMN2HPGDALOX15TDP1TPSAB1 | |
| SCHEMBL23869794 | 0.84 | SMN1; SMN2 (0.53) | SMN1; SMN2HPGDALOX15TDP1LMNA | |
| SCHEMBL23869737 | 0.81 | CYP3A4 (0.43) | SMN1; SMN2GAAHTTCYP3A4POLB | |
| SCHEMBL4470730 | 0.69 | SMN1; SMN2 (0.61) | SMN1; SMN2HPGDALOX15TDP1LMNA | |
| SCHEMBL13978026 | 0.68 | SMN1; SMN2 (0.55) | SMN1; SMN2TPSAB1LMNAGAAHTT | |
| SCHEMBL13978267 | 0.68 | SMN1; SMN2 (0.62) | SMN1; SMN2HPGDALOX15TDP1LMNA | |
| SCHEMBL9385223 | 0.67 | SMN1; SMN2 (1.00) | SMN1; SMN2HPGDALOX15TDP1LMNA | |
| SCHEMBL23869767 | 0.66 | CA1 (0.41) | GAA | |
| SCHEMBL23869786 | 0.66 | HTT (0.39) | SMN1; SMN2HPGDTDP1LMNATSHR | |
| SCHEMBL23869882 | 0.66 | SMN1; SMN2 (0.43) | SMN1; SMN2HDAC1HDAC2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20210299286-A1 | TETRAZINES FOR HIGH CLICK CONJUGATION YIELD IN VIVO AND HIGH CLICK RELEASE YIELD | TAGWORKS PHARMACEUTICALS B.V. (NL) | 2021-09-30 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20210299286-A1 | TETRAZINES FOR HIGH CLICK CONJUGATION YIELD IN VIVO AND HIGH CLICK RELEASE YIELD | FCER2, SQLE, TTL | SMN1; SMN2 4579/4885HPGD 2315/4885ALOX15 169/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.